

# TABLE OF CONTENTS

<b>Neurology I</b> .....	1
Neurology I Panel .....	3

## Epilepsy

*By Jeannine M. Conway, Pharm.D., BCPS; and Kimberly B. Tallian, Pharm.D., FCCP, BCPP*

Introduction .....	7
Pharmacotherapy .....	8
Updates in Special Populations .....	19
Emerging Treatments .....	21
Pharmacist Considerations .....	21
Conclusion .....	22
References .....	23
Self-Assessment Questions .....	26

## Status Epilepticus

*By Lisa C. Garrity, S.M., Pharm.D., BCPS<sup>a</sup>*

Introduction .....	29
Goals of Therapy .....	32
Treatment .....	32
Special Populations .....	39
Conclusion .....	40
References .....	41
Self-Assessment Questions .....	43

## CNS Hemorrhages

*By Lynn Kassel, Pharm.D., BCPS; and Dominick Salvatore, Pharm.D., BCPS*

Introduction .....	47
Pathophysiology .....	47
Diagnosis .....	48
Neurosurgical Repair .....	48
Epidural Hematoma and Hemorrhage .....	51
Acute SDHs and Hemorrhages .....	51
Chronic SDH and Hemorrhages .....	53
Subarachnoid Hemorrhage .....	54
Drug-Induced CNS Hemorrhages .....	62
Conclusion .....	68
References .....	68
Self-Assessment Questions .....	72

<b>Psychiatry I</b> .....	77
Psychiatry I Panel .....	79

## Generalized Anxiety Disorder and Panic Disorder

*By Bridget Bradley, Pharm.D., BCPP*

Introduction .....	83
Diagnosis and Patient Evaluation .....	84
Treatment Options .....	87
Guidelines for the Treatment of GAD and PD .....	90
Special Populations .....	91
Discontinuing Treatment .....	93
References .....	94
Self-Assessment Questions .....	96

## Posttraumatic Stress Disorder and Obsessive-Compulsive Disorder

*By Archana Jhawar, Pharm.D., BCPP; and Matthew Haas, Pharm.D., BCPS, BCPP*

Posttraumatic Stress Disorder .....	99
Obsessive-Compulsive Disorder .....	108
References .....	115
Self-Assessment Questions .....	116

<b>Psychiatry II</b> .....	121
Psychiatry II Panel .....	123

## Major Depressive Disorder

*By Misty L. Gonzalez, Pharm.D., BCPP*

Introduction .....	127
Identification and Treatment Goals .....	129
Nonpharmacologic Interventions .....	130
Pharmacologic Interventions .....	133
Special Populations .....	149
Pharmacogenomic Considerations .....	151
Patient Counseling Points .....	152
Conclusion .....	153
References .....	153
Self-Assessment Questions .....	155

## REMS in Psychiatry

*By Lisa W. Goldstone, Pharm.D., MS, BCPS, BCPP*

Introduction .....	159
Antipsychotics .....	160
Opioid Partial Agonists and Antagonists .....	165
Other Agents .....	167
Conclusion .....	169
References .....	169
Self-Assessment Questions .....	172